ANTI-GPC3 CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF

Title:

ANTI-GPC3 CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2023/030539

Kind Code:

A1

Abstract:

Provided herein are antibodies and antigen-binding fragment thereof targeting GPC3, and chimeric antigen receptors having one or more anti-GPC3 antigen-binding fragments thereof. Further provided are engineered immune effector cells (e.g., T cells) expressing the chimeric antigen receptors and methods of use thereof.

More Like This:

WO/1986/000909	MONOCLONAL ANTIBODY DIRECTED TO HUMAN GANGLIOSIDE GD2
WO/2019/223226	IMPROVED ANTI-CD19 CAR-T CELL
JP2023521519	Genetically modified immune cells expressing chimeric antigen receptors and having reduced inflammatory cytokine signaling

Inventors:

JIANG QINGLING (CN)
YANG SHUAI (CN)
ZHANG YAFENG (CN)
WU SHU (CN)
TU XIAOJIE (CN)

Application Number:

PCT/CN2022/117270

Publication Date:

March 09, 2023

Filing Date:

September 06, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NANJING LEGEND BIOTECH CO LTD (CN)

International Classes:

C07K19/00; C12N15/867

Foreign References:

CN107982538A	2018-05-04
CN106749675A	2017-05-31
CN111925445A	2020-11-13
CN112175085A	2021-01-05
US8497355B2	2013-07-30

Other References:

LI，C.ET AL.: "Prospect of Clinical Application of Glypican-3 Targeted Therapy for Hepatocellular Carcinoma", CHINESE JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 37, no. 2, 28 February 2021 (2021-02-28), pages 153 - 160, XP009544223
SHIMIZU，Y. ET AL.: "Next-Generation Cancer Immunotherapy Targeting Glypican-3", FRONTIERS IN ONCOLOGY, vol. 9, 10 April 2019 (2019-04-10), XP93042894

Attorney, Agent or Firm:

CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD FOR PROCESSING CHANNEL STATE INFORMATION, AND TERMINAL, BASE STATION AND COMPUTER-READABLE ST...

Next Patent: LASER PROJECTION APPARATUS